HCP Live

7 hallmark features of anxiety disorders

November 13, 2019

By Mary Beth Nierengarten, MA

Slideshow

Affecting between 15% to 20% of children and adolescents, anxiety disorders are the most prevalent psychiatric condition in pediatrics. The impact can be significant with difficulties in social and academic functioning as well as increased risk for other mental health concerns. However, it can be difficult for a clinician to differentiate between anxiety and an anxiety disorder. Here are 7 signs to help make the diagnosis.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos

John Browning, MD, provides practical skincare reminders ahead of summer season

Potential downstream benefits of RSV preventive measures, with Octavio Ramilo, MD

Discussing phase 3 data of Panzyga for PANS, with Michael Daines, MD

Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail

Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail

Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail

Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD

Related Content

Can you diagnose this 11-year-old with a petechial rash? | Image credit: Author provided

Can you diagnose this 11-year-old with a petechial rash?

Drashti Patel, BS, BA;Jyoti Budania, MD

Can you diagnose this patient? Take our poll and find out! Then check back for the full case, differential diagnosis, and correct diagnosis.

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023

FDA accepts NDA for ET-600, desmopressin oral solution for pediatric AVP deficiency | © Contemporary Pediatrics

FDA accepts NDA for ET-600, desmopressin oral solution for pediatric AVP deficiency

Morgan Ebert, Managing Editor

The FDA accepted Eton Pharmaceuticals' NDA for ET-600 for pediatric arginine vasopressin deficiency, with a target action date in February of 2026.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022

AAP, other medical societies sue HHS, Robert F. Kennedy Jr. over vaccine advices | Image Credit: © Rafael Henrique - © Rafael Henrique - stock.adobe.com.

AAP, other medical societies sue HHS, Robert F. Kennedy Jr. over vaccine practices

Joshua Fitch, Senior Editor

Six medical societies, including the American Academy of Pediatrics, are suing the HHS and its Secretary to "defend vaccine policy."

FDA approves sebetralstat as first and only on-demand treatment for HAE | Image Credit: Contemporary Pediatrics

FDA approves sebetralstat as first and only on-demand treatment for HAE

Joshua Fitch, Senior Editor

Though the original target action date was not met by the FDA, KalVista's sebetralstat is now approved to treat HAE in patients 12 years and older.

Related Content

Can you diagnose this 11-year-old with a petechial rash? | Image credit: Author provided

Can you diagnose this 11-year-old with a petechial rash?

Drashti Patel, BS, BA;Jyoti Budania, MD

Can you diagnose this patient? Take our poll and find out! Then check back for the full case, differential diagnosis, and correct diagnosis.

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023

FDA accepts NDA for ET-600, desmopressin oral solution for pediatric AVP deficiency | © Contemporary Pediatrics

FDA accepts NDA for ET-600, desmopressin oral solution for pediatric AVP deficiency

Morgan Ebert, Managing Editor

The FDA accepted Eton Pharmaceuticals' NDA for ET-600 for pediatric arginine vasopressin deficiency, with a target action date in February of 2026.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022

AAP, other medical societies sue HHS, Robert F. Kennedy Jr. over vaccine advices | Image Credit: © Rafael Henrique - © Rafael Henrique - stock.adobe.com.

AAP, other medical societies sue HHS, Robert F. Kennedy Jr. over vaccine practices

Joshua Fitch, Senior Editor

Six medical societies, including the American Academy of Pediatrics, are suing the HHS and its Secretary to "defend vaccine policy."

FDA approves sebetralstat as first and only on-demand treatment for HAE | Image Credit: Contemporary Pediatrics

FDA approves sebetralstat as first and only on-demand treatment for HAE

Joshua Fitch, Senior Editor

Though the original target action date was not met by the FDA, KalVista's sebetralstat is now approved to treat HAE in patients 12 years and older.

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.